Pacific Biosciences of California (NASDAQ:PACB) develops and sells advanced genetic sequencing technologies. The company’s platform is based on single-molecule, real-time (SMRT) sequencing, which is designed to produce highly accurate, long DNA reads. These reads can help researchers identify genetic variation, assemble genomes, and analyze complex biological systems that may be difficult to study using short-read sequencing methods.
PacBio’s product portfolio includes the Revio and Sequel IIe sequencing systems, SMRT Cells and other consumables, library-preparation products, and software for instrument operation, data analysis, and interpretation. The company also offers sequencing-related services and support. Its HiFi sequencing technology is used in applications such as human genomics, rare-disease research, cancer studies, infectious-disease analysis, agricultural research, and drug discovery.
Founded in 2004 and headquartered in Menlo Park, California, PacBio serves academic and government researchers, pharmaceutical and biotechnology companies, clinical laboratories, and agricultural organizations. Its products and services are marketed internationally through direct sales organizations, distributors, and other commercial partners. Christian Henry has served as the company’s president and chief executive officer.
